Warfarin-Aspirin Recurrent Stroke Study (WARSS) trial: is warfarin really a reasonable therapeutic alternative to aspirin for preventing recurrent noncardioembolic ischemic stroke?
Hankey
Graeme J
GJ
Department of Neurology, Royal Perth Hospital, Perth, Western Australia. gjhankey@cyllene.uwa.edu.au
D000925:Anticoagulants / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use*; D002545:Brain Ischemia / Q000209:etiology / Q000517:prevention & control*; D003627:Data Interpretation, Statistical; D004617:Embolism / Q000150:complications; D023381:Endpoint Determination; D006801:Humans; D016017:Odds Ratio; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic / Q000379:methods / Q000592:standards / Q000706:statistics & numerical data; D012107:Research Design / Q000592:standards; D055502:Secondary Prevention; D012680:Sensitivity and Specificity; D020521:Stroke / Q000209:etiology / Q000517:prevention & control*; D016896:Treatment Outcome; D014859:Warfarin / Q000627:therapeutic use*
D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors; D014859:Warfarin; D001241:Aspirin